Meet Our Team

Si holds a B.S. in Chemistry from the State University of New York at Binghamton (SUNY Binghamton).   

Si has over 25 years of experience in biotech and pharma industries, with a broad skill set in technical operations and CGMP manufacturing operations. Prior to joining Vector BioMed, Si spanned half of his career on the technical side within engineering and facilities, building start-ups and PAI. Soon after, Si focused on manufacturing and site operations, supporting CGMP manufacturing, OE, and site strategies. Si has held several leadership roles, including interim site head at Emergent BioSolutions, providing strategy and tactics for site growth and expansion.  

Si joined Vector BioMed (VBM) in 2025 as part of VBM’s site leadership team. He looks to facilitate and support global expansion to increase patient access to advanced therapies. 

Wayne holds a B.S. in Microbiology from the University of Maryland, College Park (UMCP). 

With over 30 years of experience spanning academia, nonprofit sectors, CDMOs, commercial, and QMS Consulting, Wayne has served as a scientist, program manager, and operations leader at organizations including Osiris Therapeutics – a stem cell manufacturer, ATCC – a nonprofit organization, MilliporeSigma (SAFC) – a CDMO, and Kite Pharma – a vector & CAR-T manufacturer. At Kite Pharma, he led efforts to establish clinical and commercial infrastructure for neoantigen (lentiviral vector and CAR-T) manufacturing. 

As Senior Director of Quality Assurance at Vector BioMed, Wayne draws on his diverse industry, nonprofit, and academia background to lead Quality and Compliance operations, with the goal of making affordable cell and gene therapies accessible worldwide. 

Shashi received his Bachelor’s in Chemistry from The University of Virginia, Master’s in Physiology from the Medical College of Virginia at Virginia Commonwealth University, and his MBA and Master’s in Information Systems from the Smith School of Business at the University of Maryland. He was awarded a fellowship at NIH/NICHD studying tRNA processing while attaining his molecular biology training. 

Shashi began his scientific career at Celera Genomics and was one of the many scientists to help sequence the human genome. In 2003, he transitioned to project management and over the next 20 years, built successful project management teams at various companies including Applied Biosystems, Thermo Fisher Scientific, and IDT Biologika. 

Prior to IDT Biologika, Shashi led teams in bioinformatic and clinical trial project management. As VP of Business and Project Management at IDT Biologika, Shashi supported over 40 different viral vaccine programs through Phase I and II clinical trials. He also directed the contracts team and collaborated with the business development team to engage and negotiate with clients to generate service agreements. He currently serves as the Senior Director of Business Development at Vector BioMed.

Jakob worked as a Researcher/Reviewer at FDA between 2008 and 2022. His laboratory work at FDA/CBER focused on issues related to the safety and manufacture of lentiviral vectors. Jakob’s regulatory work involved reviewing Pre-IND, INTERACT and IND submissions. He also engaged in informal consultations within the FDA and with sponsors. He was involved in numerous Regulatory Policy Activities, and he gave Regulatory Presentations both at FDA and at Scientific Meetings, including ASGCT. 

He participated in the review of multiple CAR T-cell BLAs involving gamma retroviral vectors and lentiviral vectors. He chaired the BLA for ZYNTEGLO™ (betibeglogene autotemcel), an autologous hematopoietic stem cell-based gene therapy for β-thalassemia.  The ZYNTEGLO BLA was approved by FDA in August of 2022. 

Jakob joined Vector BioMed (VBM) in March of 2023 as Senior Director, Regulatory Affairs to provide regulatory support, both internally and externally.  

For over 30 years, Kim has been successfully executing commercial plans to strategically capture emerging markets. Adept at building nimble and dynamic sales teams that deliver differentiated products, her skills have enabled customers to innovate and achieve success more rapidly. 

Her broad technical expertise spans academic research, pharmaceutical drug discovery, commercial process development, and CGMP production for consumables, benchtop and bioprocessing equipment. This includes many multi-million-dollar milestone projects to deliver custom automation and service solutions. 

Prior to joining Vector BioMed, Kim developed and implemented field sales practices to navigate the intricacies of CGMP material sales at HemaCare/CRL and Akron Biotech, leading to growth significantly above market rates. Her ability to craft resonant technical messaging, establish collaborative environments, and effectively focus early-stage sales efforts was built on her past experiences managing teams at Sartorius/TAP Biosystems, Invitrogen, and Molecular Devices. 

Kim received her Bachelor’s in Chemistry from Northwestern University. 

Indraneel received his PhD from The Feinberg Graduate School of the Weizmann Institute of Science, Israel, in the field of Molecular Genetics.

Upon completion of his Graduate Studies, Indraneel joined the field of Drug Discovery, working with various leading pharmaceutical companies like the TATA group, Glenmark Pharmaceuticals and Sun Pharmaceuticals in the field of Neurodegeneration, Inflammation and Oncology. 

Indraneel brings twenty-two plus years of experience in the field of drug development.

Indraneel’s extensive experience in academia and industry lead to his unique understanding and identifying of significant gaps that needed to be bridged for successfully addressing the affordability and accessibility of niche therapeutic areas in LMIC countries, ensuring quality healthcare for all.

Kathy received her undergraduate degree in Biology from Eastern College (University). 

She began her career as a research technician at The Wistar Institute and UCLA before moving into laboratory testing (CLIA) and Quality Control (QC). Kathy gained experience at several biotech startup companies – Molecular Oncology, Inc and OncorMed, before joining the QC department at Advanced Bioscience Laboratories. 

Kathy gained valuable experience as the Director of QC for the Virxsys Corporation, where she supported the first Phase I human clinical trial of a Lentiviral gene therapy product. In this role, Kathy was responsible for leading the QC team in qualifying methods and performing GMP lot release assays on in process and final lentiviral vector product, in addition to testing HIV-positive autologous T cell products, patient screening and monitoring samples.  

Kathy continued her focus in Lentiviral vectors when, in 2005, she joined Lentigen Technology, Inc (a Miltenyi company) as the Director of QC where she oversaw tremendous growth and success during her 17-year tenure. During this time, Kathy’s responsibilities spanned nearly every facet of QC, including assay transfer, testing of preclinical samples and GMP product release, vector stability program, and environmental monitoring. 

Carlo is a biopharmaceutical leader specializing in CGMP biologics and lentiviral manufacturing, process systems, and compliance. He’s committed to innovation, teamwork, and execution.  

Carlo started his life science career in 2006 with Human Genome Sciences (acquired by GSK in 2012) as a Manufacturing Associate on the Purification team. During his 15-year tenure, Carlo held various technical and leadership roles in manufacturing, process development and engineering, supporting clinical and commercial manufacturing of monoclonal antibodies. Carlo applied his valuable CGMP knowledge and experience to Lentiviral vector manufacturing when he joined Lentigen, a Miltenyi company, in 2020 as Manager and then Associate Director of Manufacturing. He now serves as the Director of Manufacturing at Vector BioMed. 

Carlo has an MBA from the University of Maryland Global Campus and a B.S. in Mechanical Engineering from Mapua University in the Philippines. 

With over 14 years of Life Sciences and Cell and Gene Therapy experience, Bryce began in the healthcare sector at the Cleveland Clinic within their Lerner Research Institute developing cell-based products for both civilian and military (complex wound) applications.

Bryce carried over his project management and product development experience into Life Sciences at Corning Life Sciences (prominent pillar of Corning, Inc.) as a Product Manager – managing the lifecycle of hundreds of cell culture products – for years before joining the biotech start-up world. Getting his first look at development services, he was the Product Manager for RoosterBio’s hMSC-based products. From there, Bryce took his infatuation with innovation, product development, manufacturing, and operational excellence to the CDMO / CMO industry.

In 2020, Bryce led the positioning and go-to-market strategy for Miltenyi Bioindustry (a CDMO under the Miltenyi umbrella). There, Bryce interacted with various past Lentigen employees, including much of Vector BioMed’s current leadership team. After facilitating rapid growth for Miltenyi’s CDMO business, Bryce took on a Director of Global Marketing role at KBI Biopharma and led his team to achieve various industry awards and recognition on top of successfully launching key platforms and sub-brands.

At Vector BioMed, Bryce leads global Marketing and Communications efforts to grow the brand and market presence.

Bryce holds a Master of Science in Entrepreneurial Biotechnology (Biology) from Case Western Reserve University.

Shiela received a B.A. in Organizational Management from Concordia College. She brings over 30 years of experience in finance and accounting for businesses and manufacturers, including 8 years of direct experience with CDMOs (lentiviral vector manufacturing) and CROs. Shiela’s broad skills and expertise include financial statement preparation and analysis, full-cycle accounting, project/cost accounting, inventory/production control, and procurement.

Jackie earned her undergraduate degree in Biology at Virginia Tech. 

She began her career with the Henry Jackson Foundation at the Military HIV Research Program (MHRP). In the Cytotoxic T Cell laboratory, she focused on ELISpot & Flow cytometry to support numerous HIV clinical trials and vaccine development efforts in small mammals. There, she developed a passion for vaccine research and cellular immunology. She spent the next 7 years at Aeras, a global, non-profit organization with the mission to develop an affordable TB vaccine for LMICs. In the Translational Immunology & Biomarkers group, she managed small animal & NHP immunogenicity and efficacy studies and supported clinical trials. Here she also had the opportunity to support small clinical trials as a Project Manager. 

In 2016, Jackie transitioned to Project Management at Precigen, where she served as Project Manager for Precigen’s Gorilla Adenovector portfolio.  In this role, her team successfully moved two products into the clinic while simultaneously producing clinical material on-site. One of the products, PRGN-2012, went from concept to clinic in 18 months and was eventually commercialized as Papzimeos™. 

Prior to joining Vector Biomed, Jackie spent two years at Integrated Biotherapeutics (IBT) managing a large government contract for the development of an Ebolavirus therapeutic as well as numerous projects with IBT’s key client.

Chuong, a true Materials Management professional, provides Vector BioMed with 20+ years of experience supporting CGMP manufacturing of biologics, including contract manufacturing. Chuong began his career in Material Management at Nabi Biopharmaceuticals where he supported the Clinical Operations Group and CGMP Manufacturing operations for six years. He then moved to Aeras, a non-profit organization focused on the development of tuberculosis vaccines where during his eight-year tenure, he developed, implemented, and managed the Materials Department to support a new CGMP manufacturing facility. When IDT Biologika acquired the facility in 2015, Chuong remained to support their contract manufacturing operations until 2020 when he moved to Cognate Bioservices where he established the Material Management Department to support an upcoming CGMP manufacturing facility.  

Prior to joining Vector BioMed, Chuong spent two years at Sanaria supporting CGMP manufacturing for their malaria vaccine candidate.